Metformin use and lung cancer survival: a population-based study in Norway.

ABSTRACT:

Background

We assessed associations between metformin use and survival in a nationwide Norwegian cohort of lung cancer (LC) patients.

Methods

The study linked 22,324 LC patients from the Cancer Registry of Norway diagnosed 2005-2014 with the Norwegian Prescription Database. We estimated associations of pre- and post-diagnostic metformin use with overall survival (OS) and LC-specific survival (LCSS) using multivariable time-fixed and time-dependent Cox regression.

Results

Pre-diagnostic metformin use was not associated with improved survival in all patients. Nevertheless, pre-diagnostic metformin use was associated with better LCSS in squamous cell carcinoma (SCC) patients (hazard ratio (HR) = 0.79; 95% confidence interval (CI) 0.62-0.99) and in patients with regional

SUBMITTER: Brancher S 

PROVIDER: S-EPMC7921644 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature